https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
As per Cognitive Market Research's latest published report, The Global Pertussis Vaccine market was valued at USD 5.06 Billion in 2022 and will reach USD 7.35 Billion by 2030, registering a Compound Annual Growth Rate of 5.47% for the forecast period 2023-2030. The Driving Factor of the Pertussis Vaccine Market
Increasing prevalence of pertussis
Rising prevalence of pertussis globally is expected to drive the market growth over the forecasted period. As per the WHO, over 151,000 pertussis cases were reported worldwide in 2018 and 86% of the worldwide target population received the recommended three doses of the DTP-containing vaccination during infancy as of 2018. Thus, the rising number of pertussis infections across the globe is propelling the growth of the pertussis vaccine market.
The increase in strategic activities by key market players
In order to introduce new goods, major market players are using strategies including partnerships and collaborations; this is anticipated to propel the pertussis vaccine market throughout the course of the projected year. For instance, in June 2021, the French multinational pharmaceutical and healthcare firm Sanofi announced a partnership with the American multinational pharmaceutical business Merck & Co., Inc. to produce vaccines for diseases including Tetanus and diphtheria.
The Restraining Factor of Pertussis Vaccine Market
High cost associated with vaccine developments
The high cost of vaccine development and inadequate access to vaccines in developing countries is the main factor hampering the market growth. For instance, as per the Centers for Disease Control and Prevention (CDC) in July 2023, the cost of Quadracel, a DTaP-IPV vaccine manufactured by Sanofi Pasteur, a vaccines division of the French multinational pharmaceutical company Sanofi, is US$ 61.12 for a single vial. Additionally, new markets provide the captivating potential for the major industry participants in the pertussis vaccine market.
Impact of the COVID-19 pandemic on the Pertussis Vaccine Market:
Since December 2019, the COVID-19 virus pandemic has spread to more than 100 nations, and on January 30, 2020, the World Health Organization proclaimed it to be a public health emergency.
COVID-19 has influenced the economy in three key ways which caused a direct impact on medication, vaccine demand and production, interruptions in the distribution channel, and financial impact on businesses and financial markets. In various nations, including China, India, Saudi Arabia, Egypt, the United Arab Emirates, and others, the transit of medicines and vaccinations from one location to another was challenging due to countrywide lockdowns. Quarantine, travel restrictions and social distancing policies are anticipated to cause a sharp fall in consumer and company expenditure. Additionally, hospitalization delays occurred as fewer patients visited the hospital, which was anticipated to have an impact on the worldwide market for pertussis vaccine. Introduction of Pertussis Vaccine Market
Pertussis is a respiratory disease, usually known as whooping cough, is caused by the bacteria Bordetella pertussis. The major way that pertussis transmits from one person to another is by coughing or sneezing droplets. Infants are especially vulnerable to the disease and it is a major cause of illness and mortality in this age range. Whooping cough is typically treated with the pertussis vaccine. The pertussis vaccine encompasses two main types: whole-cell vaccines and acellular vaccines. This vaccination is only accessible when combined with other immunizations. The Pertussis Vaccine is the most reliable and economical means of maintaining a pertussis-free environment. The World Health Organization has included the tetanus vaccine on the list of essential medicines because it has helped reduce the prevalence of tetanus in the US by 95% since it was first introduced in 1924.
The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.
Not seeing a result you expected?
Learn how you can add new datasets to our index.
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
As per Cognitive Market Research's latest published report, The Global Pertussis Vaccine market was valued at USD 5.06 Billion in 2022 and will reach USD 7.35 Billion by 2030, registering a Compound Annual Growth Rate of 5.47% for the forecast period 2023-2030. The Driving Factor of the Pertussis Vaccine Market
Increasing prevalence of pertussis
Rising prevalence of pertussis globally is expected to drive the market growth over the forecasted period. As per the WHO, over 151,000 pertussis cases were reported worldwide in 2018 and 86% of the worldwide target population received the recommended three doses of the DTP-containing vaccination during infancy as of 2018. Thus, the rising number of pertussis infections across the globe is propelling the growth of the pertussis vaccine market.
The increase in strategic activities by key market players
In order to introduce new goods, major market players are using strategies including partnerships and collaborations; this is anticipated to propel the pertussis vaccine market throughout the course of the projected year. For instance, in June 2021, the French multinational pharmaceutical and healthcare firm Sanofi announced a partnership with the American multinational pharmaceutical business Merck & Co., Inc. to produce vaccines for diseases including Tetanus and diphtheria.
The Restraining Factor of Pertussis Vaccine Market
High cost associated with vaccine developments
The high cost of vaccine development and inadequate access to vaccines in developing countries is the main factor hampering the market growth. For instance, as per the Centers for Disease Control and Prevention (CDC) in July 2023, the cost of Quadracel, a DTaP-IPV vaccine manufactured by Sanofi Pasteur, a vaccines division of the French multinational pharmaceutical company Sanofi, is US$ 61.12 for a single vial. Additionally, new markets provide the captivating potential for the major industry participants in the pertussis vaccine market.
Impact of the COVID-19 pandemic on the Pertussis Vaccine Market:
Since December 2019, the COVID-19 virus pandemic has spread to more than 100 nations, and on January 30, 2020, the World Health Organization proclaimed it to be a public health emergency.
COVID-19 has influenced the economy in three key ways which caused a direct impact on medication, vaccine demand and production, interruptions in the distribution channel, and financial impact on businesses and financial markets. In various nations, including China, India, Saudi Arabia, Egypt, the United Arab Emirates, and others, the transit of medicines and vaccinations from one location to another was challenging due to countrywide lockdowns. Quarantine, travel restrictions and social distancing policies are anticipated to cause a sharp fall in consumer and company expenditure. Additionally, hospitalization delays occurred as fewer patients visited the hospital, which was anticipated to have an impact on the worldwide market for pertussis vaccine. Introduction of Pertussis Vaccine Market
Pertussis is a respiratory disease, usually known as whooping cough, is caused by the bacteria Bordetella pertussis. The major way that pertussis transmits from one person to another is by coughing or sneezing droplets. Infants are especially vulnerable to the disease and it is a major cause of illness and mortality in this age range. Whooping cough is typically treated with the pertussis vaccine. The pertussis vaccine encompasses two main types: whole-cell vaccines and acellular vaccines. This vaccination is only accessible when combined with other immunizations. The Pertussis Vaccine is the most reliable and economical means of maintaining a pertussis-free environment. The World Health Organization has included the tetanus vaccine on the list of essential medicines because it has helped reduce the prevalence of tetanus in the US by 95% since it was first introduced in 1924.